Engflag

Humalog Mix

Quick links to important sections

Humalog Mix

Humalog Mix_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Humalog Mix

Property Description
Active Ingredients Insulin Lispro, Insulin Lispro Protamine
Form Suspension for Injection
Pharmacological Class Biphasic Insulin Analogue
Common Use Management of Blood Glucose Levels
Origin Synthetic (Recombinant DNA Technology)

Humalog Mix is a specialized prescription-only medicine and an antidiabetic agent utilized for managing high blood sugar levels (hyperglycemia). It is clinically recognized as a biphasic insulin analogue, meaning it is formulated to deliver two distinct insulin actions in a single subcutaneous injection. This dual-action approach is central to its utility, supporting integrated glycemic control and often chosen for its convenience in structured insulin regimens.

Composition and Form: The Dual-Action Admixture

The drug is a sterile, cloudy suspension for injection containing two active components: Insulin Lispro and Insulin Lispro Protamine. Insulin Lispro is the soluble, rapid-acting component, while Insulin Lispro Protamine is the crystalline, intermediate-acting component, formed by complexing the Lispro with protamine sulfate to delay its absorption. This unique structural difference ensures a precise balance of immediate and prolonged action.

Understanding the Integrated Action of Insulin Lispro

The primary benefit of this formulation is its integrated physiological action. It facilitates both rapid onset for efficient management of post-meal glucose spikes and intermediate duration coverage to maintain stability between meals and during the night. For patients requiring both mealtime coverage and basal coverage, this dual functionality simplifies the injection routine, contributing to the goal of continuous, stable blood sugar management.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Humalog Mix?

Possible Side Effects and Safety Information

The information presented here reflects the adverse reactions and safety characteristics of this medication as strictly documented in official government regulatory sources, such as the FDA and EMA.

Frequency-Classified Adverse Reactions

The most prominent safety characteristic of any insulin therapy is the risk of hypoglycemia (low blood sugar), which is consistently classified as Very Common in regulatory documents. Other adverse reactions are categorized by their observed frequency:

  • Common: Reactions at the injection site (e.g., redness, swelling, itching) and lipodystrophy (changes in fatty tissue at the injection area).
  • Rare: Generalized hypersensitivity reactions, which are systemic events.
  • Frequency Not Known: Peripheral edema (swelling in the limbs) and weight gain.

Serious Adverse Reactions and Safety Considerations

Official labels identify severe hypoglycemia as a serious safety concern that, if untreated, can lead to neurological complications. Generalized hypersensitivity reactions are also documented as rare but serious immune system disorders.

Regulatory documents outline specific safety notes regarding certain patient groups. Individuals with renal (kidney) or hepatic (liver) impairment may have an altered metabolism of insulin, which can increase the risk of hypoglycemia. Similarly, older adults may have a higher sensitivity to insulin, requiring clinical attention to manage this risk.

Safety patterns related to exposure are also noted. Localized injection site reactions and the frequency of hypoglycemia may be more frequently observed at the beginning of treatment. Conversely, lipodystrophy is noted as an adverse reaction associated with long-term insulin exposure.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Insulin Lispro Protamine and Insulin Lispro (Humalog Mix) results in a dose-dependent intensification of the drug’s primary action, leading to hypoglycemia (low blood sugar). This condition constitutes the official, documented presentation of overdose found in regulatory prescribing information.

Documented Manifestations and Severe Outcomes

The initial signs of overdose-induced hypoglycemia include a range of manifestations such as shakiness, confusion, excessive sweating, dizziness, headache, and a fast heartbeat. If unaddressed, this may progress to a state of Severe Hypoglycemia, which is classified as a life-threatening risk. Officially documented severe outcomes include seizures and loss of consciousness (coma). Furthermore, insulin overdosage carries the potential for severe hypokalemia (low blood potassium), a separate documented metabolic risk that can be fatal if untreated.

Required Emergency Action

Regulatory guidance mandates that individuals who experience symptoms of severe hypoglycemia or any associated complications, such as seizures or unconsciousness, must seek immediate medical attention. The official procedural response involves symptomatic and supportive treatment, including the administration of glucose or glucagon, and requires increased frequency of blood glucose monitoring and observation of potassium levels. Specific patient populations, including those with renal or hepatic impairment, have an officially documented need for heightened monitoring during management.

Therapeutic Uses of Humalog Mix

What Humalog Mix Treats: Main Uses and Benefits

Humalog Mix is commonly used for the long-term management of Type 1 and Type 2 Diabetes Mellitus, addressing the core clinical condition of chronic hyperglycemia. This biphasic insulin is commonly used for managing blood sugar levels in adults with diabetes. This therapeutic application plays a role in managing comprehensive insulin replacement therapy, which supports overall metabolic stability and may assist with easing the total glucose load. The primary indications are for patients requiring support for rapid glucose peaks and sustained baseline elevation.

This medication is generally relevant for managing two critical symptomatic domains: the rapid glucose peaks that follow meals and the sustained baseline elevation of glucose between meals and overnight. The dual action helps stabilize these fluctuating blood sugar patterns, which may assist with maintaining functional stability and supports consistent day-to-day glucose management when symptoms associated with acute or episodic changes become more disruptive.

This approach contributes to the simplification of the daily injection routine. This supports the patient by easing the overall symptom burden and assists with maintaining stability when symptoms that interfere with daily functioning become more noticeable. This formulation is considered relevant for individuals who require comprehensive mealtime and overnight glucose support.

Quick Fact: Application for Dual Glucose Burdens

Humalog Mix is applied in clinical settings that involve the need for intensified insulin support, addressing both the rapid glucose peaks and the persistent inter-meal high glucose levels.

Eligibility and Restrictions for Use

Humalog Mix is an insulin analogue indicated for use in adults with diabetes mellitus to control high blood sugar levels. Eligibility for this medicine is strictly defined by regulatory bodies through specific contraindications and conditional use requirements.

Official Eligibility Constraints

Classification Rule (As Stated in Regulatory Labels)
Absolute Contraindication Must not be used during episodes of hypoglycemia (low blood sugar).
Contraindicated in patients with known hypersensitivity to insulin lispro or any of the excipients.
Age-Related Status Safety and effectiveness have not been established in the pediatric population (children under 18 years of age).
Conditional Use Patients with renal or hepatic impairment require careful glucose monitoring and potential dose adjustments.
Comorbidity Restriction Use with Thiazolidinediones (TZDs) requires patients to be observed for signs and symptoms of heart failure.

Pregnancy and Lactation Status: Good blood glucose control is essential during pregnancy, and careful monitoring is required. Breastfeeding mothers may require adjustments to their insulin dose or diet.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Humalog Mix's effect on blood glucose is subject to interactions with a wide variety of medicinal products and substances, necessitating careful monitoring when used concomitantly.

Product Category Interaction Implication
Enhance Glucose-Lowering Effect Increased risk of hypoglycemia (low blood sugar).
Decrease Glucose-Lowering Effect Increased risk of hyperglycemia (high blood sugar).

Interacting Product Categories

The risk of hypoglycemia may be increased by co-use with other antidiabetic agents, salicylates (e.g., high-dose aspirin), certain antibiotics (sulfonamides), angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), fibrates, and monoamine oxidase inhibitors (MAOIs). Conversely, the glucose-lowering effect may be diminished by products that raise blood sugar, such as corticosteroids, diuretics, estrogens, oral contraceptives, thyroid hormones, and atypical antipsychotics. Alcohol consumption may also increase or decrease the glucose-lowering effect.

Critical Interaction Constraints

Concomitant use with Thiazolidinediones (TZDs), such as pioglitazone, requires mandatory observation for signs and symptoms of fluid retention or heart failure; dose reduction or discontinuation of the TZD may be required if heart failure develops. Additionally, medicines that blunt the signs of hypoglycemia, such as beta-blockers, may make it more difficult to recognize a low blood sugar episode. Humalog Mix is not approved for use in insulin infusion pumps and must not be mixed with any other insulins or diluents.

Mechanism of Action

Insulin Receptor Agonism and Glucose Utilization

Humalog Mix's active components function as agonists, binding to the insulin receptor (IR) on the surface of primary metabolic cells, including those in the liver, muscle, and adipose tissue. This binding activates the receptor's intrinsic tyrosine kinase domain, initiating intracellular signaling cascades, such as the PI3K/Akt pathway. This cascade facilitates the translocation of glucose transporters (e.g., GLUT4) to the cell membrane, which increases the rate of glucose uptake from the bloodstream. Simultaneously, this signaling pathway suppresses the liver's production of new glucose (gluconeogenesis). The collective action of these pathways results in a reduction of circulating blood glucose levels.

Biphasic Absorption Kinetics

The formulation contains two insulin lispro components with differing absorption kinetics: a soluble, rapidly-dissociating form and a slower-dissolving Insulin Lispro Protamine form. This blend creates a biphasic time-action profile. The rapid component provides an accelerated onset of insulin activity corresponding to postprandial glucose surges. The intermediate component provides a sustained background insulin activity to regulate glucose availability over a longer duration.

Promotion of Anabolic Processes

Activation of the IR further orchestrates a shift toward anabolism, promoting the storage of glucose as glycogen in the liver and muscle. It also regulates the synthesis of fatty acids in adipose cells and stimulates protein synthesis in muscle tissue, influencing overall substrate storage influenced by the insulin signaling pathway.

Dosage and Administration Information

Administration Overview

Humalog Mix is a pre-mixed insulin suspension designed for subcutaneous injection. It consists of a combination of insulin lispro solution and insulin lispro protamine suspension. Proper administration is necessary to ensure the medication works as intended.

Preparation of the Suspension

Before use, the insulin suspension must be uniform. This is achieved by gently rolling the vial or pre-filled pen between the palms and inverting it. The goal is to mix the contents until the liquid appears uniformly cloudy or milky. If the suspension remains clear or contains clumps, granules, or white particles that stick to the bottom or wall of the container, the medication should not be used.

Injection Technique

Humalog Mix is administered via subcutaneous injection into the fatty tissue of the body. Common injection sites include:

  • The abdomen
  • The upper arms
  • The buttocks
  • The thighs

To help maintain skin health and ensure consistent absorption, injection sites should be rotated within the same general area so that the same site is not used more than approximately once a month.

Subcutaneous Administration Only

This specific insulin formulation is intended only for subcutaneous injection. It must not be administered intravenously or via an insulin infusion pump. Care should be taken to ensure that a blood vessel is not entered during the injection process. Following the injection, the site should not be massaged.

Mixing and Compatibility

Humalog Mix is a fixed-ratio combination product. It is not intended to be mixed with other insulin formulations or diluted, as this can change the action profile and stability of the suspension.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Humalog Mix

Evidence for Use in Type 1 and Type 2 Diabetes

Research exploring the use of Humalog Mix was evaluated in studies involving adults with both Type 1 and Type 2 Diabetes. This evidence base primarily consists of Randomized Controlled Trials (RCTs), designed to compare the biphasic insulin analogue against other insulin regimens, particularly older premixed human insulins.

The trials monitored key outcomes related to functional imbalance, specifically measuring three main blood sugar markers: Glycosylated Hemoglobin (HbA1c), Fasting Plasma Glucose (FPG), and post-meal glucose fluctuation (PPG). In studies comparing the biphasic analogue to older premixed human insulins, research described patterns where HbA1c measurements were reported at comparable levels. However, research highlights changes related to post-meal glucose, with some studies describing patterns of measured postprandial glucose excursions that differed when compared to the older insulin.

Research in Special Populations

Research has also explored the use of this formulation in patient groups beyond the general adult population. Research examined outcomes in children and adolescents, with studies including populations as young as 2 years old, reflecting research conducted in pediatric diabetes settings.

For Gestational Diabetes Mellitus (GDM) and Type 2 Diabetes during pregnancy, the study landscape differs. Research in this specialized area often relies on smaller, prospective trials or retrospective observational studies. Researchers examined both maternal and perinatal outcomes, which are outcomes reflecting functional imbalance for both the mother and the unborn baby. Evidence is limited due to the challenges of studying this patient group.

Research Gaps and Areas of Uncertainty

Certainty remains low in some areas. The main clinical trials were typically conducted over intermediate-term durations (16 to 26 weeks). While these outcomes are well characterized, there is limited information for long-term outcomes that track effects over many years. The long-term effects are not fully characterized regarding complications such as cardiovascular outcomes or microvascular changes. Additionally, comparative evidence is often limited to indirect data when assessing outcomes against every single one of the newer, very long-acting basal insulin analogues.

Key Studies & References A randomized trial of insulin lispro mix 75/25 versus human insulin 70/30 in the treatment of type 1 diabetes mellitus (Pivotal Comparative RCT)

Frequently Asked Questions (FAQ)

Common questions about Humalog Mix (FAQ)

Q: How quickly does Humalog Mix typically start working after injection?

Official product information indicates that Humalog Mix typically begins to work within 10 to 15 minutes after injection, reflecting the action of the rapid-acting component in the mixture. The overall time that the insulin is active in the body is intended to be longer due to the intermediate-acting component.

Q: Can Humalog Mix be taken at a time other than before a meal?

According to the official administration guidelines, a dose of Humalog Mix is intended to be administered by subcutaneous injection within 15 minutes before a meal or other caloric intake. If guidance is needed on the precise timing of the dose relative to food intake, it is appropriate to consult a healthcare provider.

Q: Can using Humalog Mix increase the risk of developing a rash or swelling?

Regulatory documents state that injection site reactions such as redness, swelling, or itching at the injection location are a common side effect. Generalized hypersensitivity reactions (systemic rash or widespread swelling) are rare but potentially serious. If symptoms of a severe systemic reaction are observed, emergency medical assistance should be sought immediately, as described in the warnings.

Q: Is Humalog Mix a suitable option for children with diabetes?

The official prescribing information indicates that the safety and effectiveness have not been established in the pediatric population (children younger than 18 years old). The official documentation indicates that use in children requires clinical oversight to assess potential risks versus benefits.

Q: Do older adults or seniors use this premixed insulin?

Older adults may use this medication, but official safety notes caution that they may have an increased sensitivity to insulin. For this reason, older adults may require clinical oversight regarding dose adjustment, as noted in the label.

Q: Is the safety profile of Humalog Mix different for pregnant individuals?

Good control of diabetes is essential during pregnancy. The medication has not been tested in pregnant women, and consultation with a doctor is appropriate for individuals who are planning pregnancy or nursing.

Q: How is Humalog Mix distinguished from Humalog KwikPen?

The Humalog KwikPen is a specific type of prefilled, disposable pen device that is designed to deliver the Humalog Mix insulin product. The KwikPen is the mechanism used for the injection, and it contains the same insulin mixture as other forms of Humalog Mix.

Q: What does the research say about the long-term safety profile of this medication?

Studies used for regulatory approval were primarily conducted over intermediate-term durations, typically lasting 16 to 26 weeks. Because of this, limited information is available for tracking the effects of the medication over many years, and long-term effects on complications are not fully characterized.

Q: What is the main difference between Humalog Mix and regular Humalog (insulin lispro)?

Humalog Mix is classified as a biphasic suspension because it is a blend containing both rapid-acting insulin and intermediate-acting insulin (lispro protamine). In contrast, regular Humalog is strictly the single, rapid-acting insulin component (lispro) intended only for meal coverage.

Q: Is Humalog Mix the same drug as other premixed insulins like Novolog Mix?

Humalog Mix and Novolog Mix are different prescription drugs. Humalog Mix contains the active ingredient Insulin Lispro, while Novolog Mix contains Insulin Aspart. These are different insulin analogues, and substitution requires the direction of a healthcare professional.

Q: What is the maximum duration of action for the components in Humalog Mix?

Official information indicates that the overall duration of action for the components in Humalog Mix is generally up to 10 to 16 hours. Depending on the specific formulation and individual factors, the effect may last up to 24 hours.

Q: What are the signs of an allergic reaction to this medication?

Signs of a serious allergic reaction may include rash, hives, or swelling of the face, lips, tongue, or throat, along with trouble breathing or a fast heartbeat. If symptoms of a severe systemic reaction are observed, emergency medical assistance should be sought immediately, as described in the warnings.

Q: Does this insulin mix cause blurred vision in some users?

Blurred vision is listed in regulatory documents as a potential symptom of hypoglycemia (low blood sugar). Hypoglycemia is classified as the most common adverse reaction associated with insulin therapy and may cause temporary vision changes.

Q: Is it true that certain dietary supplements can change how this medicine works?

Official drug interaction warnings caution that many substances can affect blood sugar levels. The regulatory label advises patients to notify their doctor about all herbs, non-prescription drugs, or dietary supplements used, as these items may interact with the insulin.

Q: What is the usual advice for people who become sick while using Humalog Mix?

Illness, especially with nausea or vomiting, can change a person's insulin requirements. Patients are advised to have a sick day plan established with their doctor, test blood glucose and ketones frequently, and consultation with a healthcare provider is appropriate for guidance.

Q: What should someone do if they believe their insulin pen is not working properly?

The instructions advise patients to prime the pen before each dose to ensure insulin is flowing correctly. If problems persist, such as an inability to see insulin come out during priming, or if the pen is visibly damaged, the official instructions advise users to contact their healthcare professional.

Q: Is Humalog Mix available in different strengths?

Humalog Mix is available in different mix ratios of the two components to suit a patient’s needs. Common formulations include 75% lispro protamine / 25% lispro (Mix 75/25) and 50% lispro protamine / 50% lispro (Mix 50/50).

Q: Does the color of the pen mean anything?

The pen is manufactured in a specific color with a distinctive dose knob and label. This consistent design is used by the manufacturer and regulators to help users distinguish the product and reduce the likelihood of medication errors.

Q: Where can I find information about the clinical trials for Humalog Mix?

The full prescribing information available through the FDA and NIH provides the regulatory tracking numbers and references for the specific clinical studies used to approve the drug. These references can be used by the public to locate the detailed trial summaries.

Q: Why is Humalog Mix only available by prescription?

As a potent drug that requires precise, individualized dosing, and due to its potential to cause serious adverse events like severe hypoglycemia, it is classified by regulatory bodies as a prescription-only medicine. This classification ensures that its use is supervised by a qualified healthcare professional.

Q: What is the purpose of the patient information leaflet that comes with the insulin?

The patient information leaflet, or Medication Guide, is a mandatory regulatory document required by agencies like the FDA. Its purpose is to inform the patient about the proper use, storage, risks, and warnings associated with the medication in clear, non-technical language.

Q: Is Humalog Mix associated with any specific warnings about potassium levels?

Yes. All insulins, including Humalog Mix, carry a serious warning because they can cause a shift in potassium from the blood into the cells. This process can potentially lead to hypokalemia (low blood potassium), which is a serious warning documented in the safety information.

Q: Are there any restrictions on driving or operating machinery mentioned in the safety information?

Yes. The safety information includes a caution regarding driving or operating machinery until the patient knows how the medication affects them. This warning is specifically due to the risk of hypoglycemia (low blood sugar) which can impair concentration and reaction time.

How should Humalog Mix be stored and disposed of?

How to Store and Dispose of Humalog Mix

Unopened Humalog Mix must be stored in a refrigerator between 36 F and 46 F (2 C and 8 C) and protected from light. The product must not be frozen; any frozen insulin must be discarded.

In-Use Storage

Once opened, vials can be stored at room temperature (up to 86 F or 30 C) and must be discarded after 28 days. KwikPens and cartridges must be stored at room temperature only and should not be refrigerated once in use. KwikPens have a time-limited stability and must be discarded after their specific labeled duration (e.g., 10 or 28 days).

Disposal Instructions

All forms of Humalog Mix must be kept out of the reach of children. Used needles and syringes must be disposed of immediately in an approved, puncture-resistant sharps container. Unused or expired medication must be discarded according to local regulations, avoiding disposal in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Humalog Mix found in:

A-Z Index: